PHC Corporation Biomedical Division, a subsidiary of healthcare company PHC Holdings Corporation (TOKYO:6523), announced on Wednesday that it has introduced the LiCellMo live cell metabolic analyzer, designed for real-time visualization of cellular metabolism in cell and gene therapy (CGT) research. Leveraging proprietary In-Line monitoring technology, LiCellMo enables continuous measurement of cellular metabolites without disrupting the culture, addressing the need for precise metabolic analysis crucial for developing CGT products, including CAR-T therapies.

LiCellMo's capabilities are essential as the CGT sector accelerates, particularly in areas like cancer immunology and stem cell research. Traditional methods often involve repeated sampling, risking contamination and inconsistent results. LiCellMo mitigates these issues by providing uninterrupted metabolic data, allowing researchers to track cellular changes in real-time, thus facilitating more accurate process development.

Set for launch in Japan this September, followed by select international markets in October, LiCellMo integrates easily into existing lab setups, requiring only PHC's proprietary sensor module. The device supports standard cell culture environments, enabling continuous analysis of glycolysis by monitoring glucose and lactate levels. These features are expected to enhance research outcomes and contribute to the advancement of novel therapies.

PHC Corporation has conducted beta tests of LiCellMo at various research institutions and pharmaceutical companies since 2023. Feedback from these trials highlights the analyzer's ability to provide detailed insights into cellular metabolism, which were previously unattainable with conventional methods.